Fate Therapeutics Inc (FATE): Multiplikator forward rega marang pendapatan
Fate Therapeutics, Inc. (FATE) is attracting leading biologists to develop immunotherapies by supporting its scientific staff with generous RSUs and budgets. Clinical expenses are covered by existing cash reserves, a fact reflected in the forward P/S dynamics, where the latest value is recorded as 33.10. Business revenues are based on grants and payments from strategic pharmaceutical partners for the development of oncology treatments.
Rincian analitis perusahaan Fate Pharma (FATE)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi bursa:
- rincian valuasi buku bisnis:
- statistik kawajiban utang lan likuiditas:
Rasio Total Utang marang Ekuitas Fate Therapeutics, Inc.|FATE - Rasio silihan jangka dawa marang modal|Utang jangka cendhak marang modal Fate Therapeutics, Inc.|FATE - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku Fate Pharma|FATE - Utang jangka dawa|Utang jangka cendhak perusahaan Fate Therapeutics|Rasio cepet fatetherapeutics.com
- rincian asil keuangan lan kelipatan valuasi:
FATE - Bathi resik|Bathi sing dikarepake Fate Therapeutics, Inc.|FATE - Kapitalisasi marang bathi resik|Pangali Forward P/E Fate Therapeutics Corp|FATE - Rega marang bathi kanthi panyesuaian wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Fate Pharma|FATE - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan Fate Therapeutics|FATE - Bathi saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan fatetherapeutics.com|FATE - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Fate Therapeutics, Inc.
- rincian pendapatan lan dodolan:
Ringkesan analisis perusahaan:Fate Therapeutics FATE
For the biotechnology sector, where Fate Therapeutics, Inc. (FATE) is developing its iPSC platform, this indicator serves as a tool for assessing market expectations regarding future revenue. The forward P/S ratio is calculated as the ratio of current market capitalization to expected annual sales, allowing investors to use this chart to compare asset value against the potential of new alliances and clinical trial successes.
Analisis pesaing
Multiplikator Forward P/S ONC (BeiGene)|Multiplikator Forward P/S Halozyme Therapeutics, Inc. HALO|RVMD: Multiplikator forward rega marang pendapatan|Ascentage Pharma Corp - Rasio rega marang pendapatan sing dikarepake|CGON: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep urogen.com (URGN)|Multiplikator forward rega marang pendapatan BCAX|PSNL: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan ERAS (Erasca Corp)|Rasio rega marang pendapatan sing dikarepake DCTH|Multiplikator Forward P/S YMAB (Y-mAbs Therapeutics)|Rega forward marang dodolan AURA|Candel - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Accuray Inc|sellaslifesciences.com (SLS) - Rasio rega marang prakiraan pendapatan|Actuate Therapeutics Inc - Rega forward marang dodolan|CTOR (Citius Oncology, Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S TuHURA|Rasio rega marang prakiraan pendapatan Protara Therapeutics, Inc. (TARA)|WHWK: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S TCRX (TScan Therapeutics, Inc.)|Champions Oncology Inc (CSBR) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|XBIT: Multiplikator forward rega marang pendapatan|CVM - Multiplikator Forward P/S|OSTX (OS Therapies) - Multiplikator forward rega marang pendapatan|RADX: Rasio rega marang pendapatan sing dikarepake|ARTV (Artiva Biotherapeutics Inc.) - Multiplikator Forward P/S|Adlai Nortye Limited (ANL) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S VERU|Multiplikator forward rega marang pendapatan tempesttx.com TPST|Rasio rega marang prakiraan pendapatan Xilio Therapeutics XLO|Rasio kapitalisasi marang dodolan sing dikarepake Renovaro Biosciences (RENB)|MURA: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan KAPA (Kairos Pharma Ltd)|OKUR: Multiplikator Forward P/S|GDTC - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Curis Inc.|Kapitalisasi marang prakiraan pendapatan APLM (Apollomics Corp)|Multiplikator Forward P/S THAR|Multiplikator forward rega marang pendapatan advanbiomed.com ADVB|Genprex, Inc. - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Calidi Biotherapeutics Inc. (CLDI)|Sunshine Biopharma, Inc. - Multiplikator Forward P/S|Rega mangsa ngarep marang pendapatan XBIO|SLRX: Multiplikator Forward P/S|Kitov Pharma (PPBT) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan AONC|BGNE (beigene.com) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S CKPT|ELEV - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S ICAD (iCAD)|IKNA - Multiplikator forward rega marang pendapatan|Notable Labs, Ltd. - Multiplikator Forward P/S|VIRX - Multiplikator Forward P/S|MorphoSys (MOR) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan NAYA|AAPGV (Ascentage Pharma Group Ltd) - Multiplikator Forward P/S
